Abstract
Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer
Volume: 14 Issue: 1
Author(s): Joshua C. Doloff and David J. Waxman
Affiliation:
Keywords: Cancer gene therapy, cytochrome P450 prodrug activation, replication-conditional adenovirus, oncolytic adenovirus, tumor heterogeneity.
Abstract: Cancer cell heterogeneity is a common feature - both between patients diagnosed with the same cancer and within an individual patient’s tumor - and leads to widely different response rates to cancer therapies and the potential for the emergence of drug resistance. Diverse therapeutic approaches have been developed to combat the complexity of cancer, including individual treatment modalities designed to target tumor heterogeneity. This review discusses adenoviral vectors and how they can be modified to replicate in a cancer-specific manner and deliver therapeutic genes under multi-tiered regulation to target tumor heterogeneity, including heterogeneity associated with cancer stem cell-like subpopulations. Strategies that allow for combination of prodrug-activation gene therapy with a novel replication-conditional, heterogeneous tumor-targeting adenovirus are discussed, as are the benefits of using adenoviral vectors as tumor-targeting oncolytic vectors. While the anticancer activity of many adenoviral vectors has been well established in preclinical studies, only limited successes have been achieved in the clinic, indicating a need for further improvements in activity, specificity, tumor cell delivery and avoidance of immunogenicity.
Export Options
About this article
Cite this article as:
Doloff C. Joshua and Waxman J. David, Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/18715206113139990309
DOI https://dx.doi.org/10.2174/18715206113139990309 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Mycobacterial Peroxides: A New Class of Agents for Development Against Tuberculosis
Medicinal Chemistry Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging- Guided Photothermal and Photodynamic Therapy of Cancer
Current Topics in Medicinal Chemistry Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination
Current Gene Therapy Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets 8-Azapurine Nucleus: A Versatile Scaffold for Different Targets
Mini-Reviews in Medicinal Chemistry Meet Our Associate Board Member
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy for Gastric Diseases
Current Gene Therapy Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Helenalin: An Anti-Inflammatory and Anti-Neoplastic Agent: A Review
Current Bioactive Compounds FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry: An Attractive and Prospective Method for Quantitative Bioanalysis in Drug Metabolism
Current Drug Metabolism Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Current Concepts on the Management of Chordoma
Current Drug Therapy Discovery of Novel <i>N</i>-alkyl 4-anilinofuro[2,3-<i>b</i>]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers
Anti-Cancer Agents in Medicinal Chemistry Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine Preface The Urokinase-type Plasminogen Activator System in Cancer and other Pathological Conditions: Introduction and Perspective [Hot Topic: The Urokinase-type Plasminogen Activator System in Cancer (Executive Editor : S. Rosenberg)].
Current Pharmaceutical Design Electrochemical DNA Detection Using Carbon Nanotubes
Current Physical Chemistry The Effect in Topical Use of Lycogen<sup>TM</sup> via Sonophoresis for Anti-aging on Facial Skin
Current Pharmaceutical Biotechnology